983 related articles for article (PubMed ID: 9777317)
21. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
Wu JC; Chan FK; Ching JY; Leung WK; Hui Y; Leong R; Chung SC; Sung JJ
Gut; 2004 Feb; 53(2):174-9. PubMed ID: 14724146
[TBL] [Abstract][Full Text] [Related]
22. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Kuipers EJ; Nelis GF; Klinkenberg-Knol EC; Snel P; Goldfain D; Kolkman JJ; Festen HP; Dent J; Zeitoun P; Havu N; Lamm M; Walan A
Gut; 2004 Jan; 53(1):12-20. PubMed ID: 14684569
[TBL] [Abstract][Full Text] [Related]
23. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Campbell DR; Haber MM; Sheldon E; Collis C; Lukasik N; Huang B; Goldstein JL
Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
[TBL] [Abstract][Full Text] [Related]
24. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.
Graham DY
Helicobacter; 2002 Feb; 7(1):1-8. PubMed ID: 11886469
[TBL] [Abstract][Full Text] [Related]
25. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
26. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
27. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.
Wu JC; Chan FK; Wong SK; Lee YT; Leung WK; Sung JJ
Aliment Pharmacol Ther; 2002 Mar; 16(3):545-52. PubMed ID: 11876709
[TBL] [Abstract][Full Text] [Related]
28. Review of esomeprazole in the treatment of acid disorders.
Johnson DA
Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
[TBL] [Abstract][Full Text] [Related]
29. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
30. New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee.
Yeomans ND
Am J Med; 1998 Mar; 104(3A):56S-61S; discussion 79S-80S. PubMed ID: 9572322
[TBL] [Abstract][Full Text] [Related]
31. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
32. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.
Malfertheiner P; Mégraud F; O'Morain C; Hungin AP; Jones R; Axon A; Graham DY; Tytgat G;
Aliment Pharmacol Ther; 2002 Feb; 16(2):167-80. PubMed ID: 11860399
[TBL] [Abstract][Full Text] [Related]
33. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
34. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.
Hawkey CJ; Wilson I; Naesdal J; Långström G; Swannell AJ; Yeomans ND
Gut; 2002 Sep; 51(3):344-50. PubMed ID: 12171954
[TBL] [Abstract][Full Text] [Related]
35. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological management of gastro-oesophageal reflux disease.
Klinkenberg-Knol EC; Festen HP; Meuwissen SG
Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
[TBL] [Abstract][Full Text] [Related]
37. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
38. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Berstad A; Hatlebakk JG
Aliment Pharmacol Ther; 1993; 7 Suppl 1():34-6, discussion 61-6. PubMed ID: 8490077
[TBL] [Abstract][Full Text] [Related]
39. A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients: unchanged frequency of erosive oesophagitis and decreased prevalence of non-erosive gastro-oesophageal reflux disease.
Kupcinskas L; Jonaitis L; Kiudelis G
Eur J Gastroenterol Hepatol; 2004 Apr; 16(4):369-74. PubMed ID: 15028968
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
